• $102.00
    Market Cap
  • 0.00%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
09/30/2022
09/30/2021
09/30/2020
Income Statement
Total Operating Revenue
21.8M
-0.82%
21.9M
+170.11%
8.1M
N/A
Cost of Revenue
14.4M
+8.41%
13.3M
+176.10%
4.8M
N/A
Gross Profit
7.3M
-15.11%
8.6M
+161.33%
3.3M
N/A
Sales and Marketing Expense
1.8M
+54.74%
1.2M
+341.83%
265,028
N/A
Research and Development Expense
N/A
N/A
N/A
N/A
N/A
N/A
Depreciation and Amortization Expense
1.5M
+46.23%
1.0M
+680.99%
128,814
N/A
Total Operating Expenses
30.4M
+113.71%
14.2M
+62.97%
8.7M
N/A
Operating Profit
-23.1M
+311.79%
-5.6M
+3.23%
-5.4M
N/A
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
-6.4M
+21.14%
-5.3M
-23.91%
-7.0M
N/A
Interest Income and Expense and Net
-6.4M
+21.14%
-5.3M
-23.91%
-7.0M
N/A
Total Nonoperating Income and Expense
-8.1M
+52.71%
-5.3M
-37,889,450.00%
14
N/A
Income before Taxes
-31.2M
+185.77%
-10.9M
-11.95%
-12.4M
N/A
Income Taxes
13,221
-99.42%
2.3M
+2,748.17%
-85,984
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-31.2M
+185.89%
-10.9M
-11.33%
-12.3M
N/A
Net Income from Continuing Operations Applicable to Common
-31.2M
+185.89%
-10.9M
-11.14%
-12.3M
N/A
Basic EPS and Net Income
-0.33
+135.71%
-0.14
N/A
N/A
N/A
Diluted EPS and Net Income
-0.33
+135.71%
-0.14
-30.00%
-0.20
N/A
Basic Weighted Average Shares
95.7M
+21.75%
78.6M
+27.54%
61.6M
N/A
Diluted Weighted Average Shares
95.7M
+21.75%
78.6M
+27.54%
61.6M
N/A
Balance Sheet
Cash and Cash Equivalents
85,637
-94.11%
1.5M
+1,617.66%
84,677
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
85,637
-94.11%
1.5M
+1,617.66%
84,677
N/A
Total Current Assets
3.6M
-66.47%
10.6M
+266.38%
2.9M
N/A
Accumulated Depreciation
777,473
+62.20%
479,320
+79.99%
266,297
N/A
Property and Plant and Equipment and Net
21.0M
+93.23%
10.9M
+50.90%
7.2M
N/A
Total Long-Term Assets
655,598
-93.97%
10.9M
+50.90%
7.2M
N/A
Total Assets
110.8M
-5.18%
116.8M
+465.28%
20.7M
N/A
Income Taxes Payable
13,221
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
19.7M
+238.43%
5.8M
+6.41%
5.5M
N/A
Total Current Liabilities
40.6M
+170.75%
15.0M
+45.70%
10.3M
N/A
Total Long-Term Debt
7.2M
-51.75%
15.0M
+573.87%
2.2M
N/A
Total Long-Term Liabilities
8.2M
-47.60%
15.7M
+11,100.02%
140,336
N/A
Total Liabilities
48.8M
+58.99%
30.7M
+142.78%
12.6M
N/A
Retained Earnings
-65.0M
+91.94%
-33.9M
+47.48%
-23.0M
N/A
Total Stockholders Equity
62.0M
-28.04%
86.1M
+301.12%
21.5M
N/A
Total Shares Outstanding
97.7M
+3.03%
94.8M
+69.13%
56.0M
N/A
Cash Flow
Cash from Operating Activities
-2.3M
-62.36%
-6.0M
+424.75%
-1.1M
N/A
Capital Expenditures
4.3M
+93.00%
2.2M
+1,241.42%
167,152
N/A
Cash from Investing Activities
-5.2M
+31.71%
-3.9M
+341.78%
-886,854
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
6.0M
-46.39%
11.3M
+633.24%
1.5M
N/A
Financials Ratio
Gross Margin
33.61%
-14.40%
39.26%
-3.25%
40.58%
N/A
Operating Margin
-106.01%
+315.20%
-25.53%
-61.78%
-66.81%
N/A
Return on Assets
-27.40%
+72.71%
-15.87%
-77.34%
-70.01%
N/A
Return on Equity
-42.12%
+107.70%
-20.28%
-76.16%
-85.04%
N/A
Revenue Growth
-0.82%
-100.48%
170.11%
+163.28%
64.61%
N/A
Current Ratio
0.09
-87.62%
0.71
+151.48%
0.28
N/A
Cash Ratio
0.002
-97.84%
0.10
+1,082.93%
0.008
N/A
Debt-to-Equity Ratio
0.43
+79.93%
0.24
-32.61%
0.36
N/A
Debt-to-Assets Ratio
0.24
+36.56%
0.18
-52.18%
0.37
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow